Tag Archives: Asuragen

March 2022—Asuragen has launched a kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The AmplideX PCR/CE CFTR Kit, for research use only, is designed to detect about 93 percent of CFTR pathogenic variants observed in the U.S. population.

June 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.

March 9, 2021—Bio-Techne Corp. has reached an agreement to acquire Asuragen for an initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.

April 2020—The FDA authorized the marketing of AmplideX Fragile X Dx and Carrier Screen Kit (Asuragen). It is the first test, according to the FDA, to detect Fragile X syndrome, the most common known cause of inherited developmental delay and intellectual disability. Additionally, this test is intended for use in adults who may be carriers of genetic alterations in the FMR1 gene.

April 16, 2020—Asuragen has developed an Armored RNA Quant SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic.

May 2017—Asuragen entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics. Asuragen will leverage its AmplideX PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument.